- Market Capitalization, $K 5,666,578
- Shares Outstanding, K 96,551
- Annual Sales, $ 245,890 K
- Annual Income, $ -31,250 K
- 60-Month Beta N/A
- Price/Sales 23.46
- Price/Cash Flow N/A
- Price/Book 13.69
|Period||Period Low||Period High||Performance|
| || |
-18.26 (-23.73%)since 03/03/20
| || |
-16.87 (-22.33%)since 01/03/20
10x Genomics, Inc. (Nasdaq: TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company's Board of...
PLEASANTON, Calif. (AP) _ 10x Genomics Inc. (TXG) on Tuesday reported a loss of $7.1 million in its fourth quarter.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
In recent trading, shares of 10x Genomics Inc have crossed above the average analyst 12-month target price of $64.75, changing hands for $67.85/share. When a stock reaches the target an analyst has set,...
PLEASANTON, Calif. (AP) _ 10x Genomics Inc. (TXG) on Thursday reported a loss of $9.6 million in its third quarter.
10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to...
|10X Genomics Inc|
|IQ Global Resources ETF|
|Nasdaq Composite ETF|
|FTSE Developed Markets Vanguard|
|Dev Mkts Ex-US Small Cap Alphadex Fund FT|
|Extended Market Index ETF Vanguard|